Profiling analysis of circulating microRNA in peripheral blood of patients with class IV lupus nephritis
Renal involvement in Systemic Lupus Erythematous (SLE) patients is one of the leading causes of morbidity and a significant contributor to mortality. It’s estimated that nearly 50% of SLE individuals develop kidney disease in the first year of the diagnosis. Class IV lupus nephritis (LN-IV) is the c...
- Autores:
-
Navarro-Quiroz E.
Pacheco-Lugo L.
Navarro Quiroz, Roberto carlos
Lorenzi H.
España-Puccini P.
Díaz-Olmos Y.
Almendrales L.
Olave V.
Gonzalez-Torres H.
Diaz-Perez A.
Dominguez A.
Iglesias A.
García R.
Aroca-Martinez G.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2023
- Institución:
- Universidad Cooperativa de Colombia
- Repositorio:
- Repositorio UCC
- Idioma:
- OAI Identifier:
- oai:repository.ucc.edu.co:20.500.12494/49619
- Acceso en línea:
- https://doi.org/10.1371/journal.pone.0187973
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033775554&doi=10.1371%2fjournal.pone.0187973&partnerID=40&md5=c23a99dcf93d1d97810d4f2f18f95866
https://hdl.handle.net/20.500.12494/49619
- Palabra clave:
- ADOLESCENT
ADULT
AGED
ARTICLE
BLOOD SAMPLING
CLINICAL ARTICLE
COHORT ANALYSIS
COLOMBIAN
COMPARATIVE STUDY
CONTROLLED STUDY
DATA BASE
DISEASE CLASSIFICATION
DNA FINGERPRINTING
FEMALE
GENE CONTROL
GENE EXPRESSION
GENE IDENTIFICATION
GENE MUTATION
HUMAN
LUPUS ERYTHEMATOSUS NEPHRITIS
MALE
MICRORNA
MICRORNA 1260B
MICRORNA 153 3P
MICRORNA 323B 3P
MICRORNA 3942 5P
MICRORNA 4511
MICRORNA 4732 3P
MICRORNA 485 5P
MICRORNA 543
MICRORNA 584 5P
MICRORNA 589 3P
MICRORNA 6087
MICRORNA 6741 3P
MICRORNA 7977
ONSET AGE
PATHOGENESIS
RNA ANALYSIS
RNA EXTRACTION
RNA SEQUENCE
UNCLASSIFIED DRUG
- Rights
- openAccess
- License
- http://purl.org/coar/access_right/c_abf2
Summary: | Renal involvement in Systemic Lupus Erythematous (SLE) patients is one of the leading causes of morbidity and a significant contributor to mortality. It’s estimated that nearly 50% of SLE individuals develop kidney disease in the first year of the diagnosis. Class IV lupus nephritis (LN-IV) is the class of lupus nephritis most common in Colombian patients with SLE. Altered miRNAs expression levels have been reported in human autoimmune diseases including lupus. Variations in the expression pattern of peripheral blood circulating miRNAs specific for this class of lupus nephritis could be correlated with the pathophysiological status of this group of individuals. The aim of this study was to evaluate the relative abundance of circulating microRNAs in peripheral blood from Colombian patients with LN-IV. Circulating miRNAs in plasma of patients with diagnosis of LN-IV were compared with individuals without renal involvement (LNN group) and healthy individuals (CTL group). Total RNA was extracted from 10 ml of venous blood and subsequently sequenced using Illumina. The sequences were processed and these were analyzed using miRBase and Ensembl databases. Differential gene expression analysis was carried out with edgeR and functional analysis were done with DIANA-miRPath. Analysis was carried out using as variables of selection fold change (2 o -2) and false discovery rate (0.05). We identified 24 circulating microRNAs with differential abundance between LN-IV and CTL groups, fourteen of these microRNAs are described for the first time to lupus nephritis (hsa-miR-589-3p, hsa-miR-1260b, hsa-miR-4511, hsa-miR-485-5p, hsa-miR-584-5p, hsa-miR-543, hsa-miR-153-3p, hsa-miR-6087, hsa-miR-3942-5p, hsa-miR-7977, hsa-miR-323b-3p, hsa-miR-4732-3p and hsa-miR-6741-3p). These changes in the abundance of miRNAs could be interpreted as alterations in the miRNAs-mRNA regulatory network in the pathogenesis of LN, preceding the clinical onset of the disease. The findings thus contribute to understanding the disease process and are likely to pave the way towards identifying disease biomarkers for early diagnosis of LN. © 2017 Navarro-Quiroz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
---|